Patents by Inventor John W. Crabb
John W. Crabb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9957333Abstract: An isolated anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof includes a heavy chain variable domain that includes three CDRs having at least 90% sequence identity to the three heavy chain CDRs of SEQ ID NO: 7, and a light chain variable domain that includes three CDRs having at least 90% sequence identity to the three light chain CDRs of SEQ ID NO: 8.Type: GrantFiled: April 17, 2015Date of Patent: May 1, 2018Assignees: Case Western Reserve University, The Cleveland Clinic FoundationInventors: Robert G. Salomon, John W. Crabb, Yalun Cui, Nicholas D. Tomko
-
Publication number: 20160215067Abstract: An isolated anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof includes a heavy chain variable domain that includes three CDRs having at least 90% sequence identity to the three heavy chain CDRs of SEQ ID NO: 7, and a light chain variable domain that includes three CDRs having at least 90% sequence identity to the three light chain CDRs of SEQ ID NO: 8.Type: ApplicationFiled: April 17, 2015Publication date: July 28, 2016Inventors: Robert G. Salomon, John W. Crabb, Yalun Cui, Nicholas D. Tomko
-
Publication number: 20160108114Abstract: The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.Type: ApplicationFiled: October 23, 2015Publication date: April 21, 2016Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
-
Publication number: 20120230996Abstract: The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.Type: ApplicationFiled: February 9, 2012Publication date: September 13, 2012Applicant: The Cleveland Clinic Foundation and Case Western Reserve UniversityInventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
-
Patent number: 8137991Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.Type: GrantFiled: July 23, 2007Date of Patent: March 20, 2012Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Reganathan
-
Publication number: 20110003880Abstract: Provided herein is a method of inhibiting optic nerve damage in an individual in need thereof, comprising administering to the individual an agent that inhibits peptidyl arginine deiminase 2 (PAD2). In a particular embodiment, the present invention is directed to a method of inhibiting glaucomatous optic nerve damage in an individual in need thereof, comprising administering to the individual an agent that inhibits peptidyl arginine deiminase 2 (PAD2). The present invention is also directed to a method of treating glaucoma (e.g., primary open angle glaucoma) in an individual in need thereof, comprising administering to the individual an agent that inhibits (e.g., specifically inhibits) peptidyl arginine deiminase 2 (PAD2).Type: ApplicationFiled: August 12, 2008Publication date: January 6, 2011Inventors: Sanjoy K. Bhattacharya, John W. Crabb
-
Publication number: 20100143380Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.Type: ApplicationFiled: July 23, 2007Publication date: June 10, 2010Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
-
Patent number: 7560257Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(?-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.Type: GrantFiled: March 6, 2008Date of Patent: July 14, 2009Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu
-
Publication number: 20080160505Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(?-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.Type: ApplicationFiled: March 6, 2008Publication date: July 3, 2008Inventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu
-
Patent number: 7341839Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(?-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.Type: GrantFiled: September 20, 2006Date of Patent: March 11, 2008Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu
-
Patent number: 7172874Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(?-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.Type: GrantFiled: April 30, 2002Date of Patent: February 6, 2007Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu
-
Publication number: 20040265924Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(&ohgr;-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject.Type: ApplicationFiled: April 30, 2002Publication date: December 30, 2004Inventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu